Your browser doesn't support javascript.
loading
Are two Gliflozins different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin compared to Empagliflozin on Biomarkers of Heart Failure in Indian Patients of Type 2 diabetes mellitus with Chronic Heart Failure (REMIT-HF study).
Sengupta, Shantanu; Pb, Jayagopal; Mehta, Ashwani; Sawhney, Jps; Suryavanshi, Satish; Jamwal, Naveen; Kadam, Dilip; Gowda, Ambanna; Dargad, Ramesh; Bhate, Amit; Kapoor, Vinod; Bhushan, Sumit; Mane, Abhishek; Gadkari, Rujuta; Patil, Saiprasad; Barkate, Hanmant.
Afiliación
  • Sengupta S; Sengupta Hospital and Research Institute, Nagpur, India. Electronic address: senguptasp@gmail.com.
  • Pb J; Lakshmi Hospital, Palakkad, India.
  • Mehta A; Sir Gangaram Hospital, Delhi, India.
  • Sawhney J; Sir Gangaram Hospital, Delhi, India.
  • Suryavanshi S; SMC Heart Institute, Raipur, India.
  • Jamwal N; RML Institute, Lucknow, India.
  • Kadam D; Care Hospital, Pune, India.
  • Gowda A; Citizen Hospital, Bangalore, India.
  • Dargad R; Stress test clinic, Mumbai, India.
  • Bhate A; Jeevan Rekha Hospital, Belagavi, India.
  • Kapoor V; New Leelamani Hospital, Kanpur, India.
  • Bhushan S; Glenmark Pharmaceuticals, India.
  • Mane A; Glenmark Pharmaceuticals, India.
  • Gadkari R; Glenmark Pharmaceuticals, India.
  • Patil S; Glenmark Pharmaceuticals, India.
  • Barkate H; Glenmark Pharmaceuticals, India.
J Card Fail ; 2024 Aug 14.
Article en En | MEDLINE | ID: mdl-39151723
ABSTRACT

BACKGROUND:

There is limited data comparing two gliflozins on their effect on biomarkers in diabetic patients with chronic heart failure.

METHODS:

A prospective, multicenter, active controlled, double-arm, investigator-initiated, interventional study enrolled 250 adults with T2DM and comorbid CHF (LVEF<40%; NT-proBNP >600pg/ml). 125 patients were allocated each to Remogliflozin (R) and Empagliflozin (E) group and followed up for 24 weeks. The primary endpoint was the mean percentage change from baseline in NT-proBNP level after 24 weeks.

RESULTS:

There was significant improvement from baseline in mean NT-proBNP level in both groups after 24 weeks however there was no significant difference between the two groups (p= 0.214). The mean NT-proBNP level improved from 2078.15±1764.70 pg/ml at baseline to 1185.06±1164.21 pg/ml at 6 months in R-group (p≤0.001) and from 2283.98±1759.15 pg/ml at baseline to 1395.33±1304.18 pg/ml at 6 months in E-group (p= <0.001). Left ventricular ejection fraction (LVEF) and LV volumes improved in both the groups. The glycemic parameters (HbA1c, FPG and PPG) demonstrated a significant reduction from baseline to week 24 in both groups. Similar improvement was seen in heart rate, blood pressure and weight reduction over 6 months in both groups. There was no drug related serious adverse event in any group.

CONCLUSION:

Remogliflozin and Empagliflozin significantly improves glycemic parameters and NT-proBNP levels as the index of the therapeutic effects in T2DM patients with CHF. The positive effects are comparable in both groups.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Card Fail Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Card Fail Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos